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Abstract
Background: Epidermolysis bullosa (EB) is a group of rare, genetic diseases that affect the integrity of epithelial
tissues, most notably the skin. Patients experience recurrent skin wounding, with severity depending on type, sub-
type, and mutation. Oleogel-S10, a formulation of birch bark extract, has demonstrated efficacy in a Phase 2 trial
assessing re-epithelialization of wounds in EB. EASE (NCT03068780, EudraCT 2016–002066-32) is a randomized,
Phase 3, placebo-controlled study designed to determine the efficacy of Oleogel-S10 versus placebo in patients
with EB.
Methods: EASE is a Phase 3, two-phase study comprising a 90-day, double-blind, randomized, placebo-controlled
phase, followed by 24 months of open-label, single-arm follow-up. Patients with junctional EB, dystrophic EB, or
Kindler syndrome and target wounds (10 - 50cm2) present for > 21 days and < 9months, are randomized in a 1:1
ratio to receive wound dressings according to local standard of care with or without Oleogel-S10. Placebo is based
on the Oleogel-S10 vehicle, which is sunflower oil formulated to have a consistency indistinguishable from that of
the active product. The primary endpoint of the trial, directed by the US health authority according to the required
study endpoints for chronic cutaneous ulcer and burn wounds, is to compare the efficacy of Oleogel-S10 versus
placebo according to the proportion of patients with complete closure of the target wound within 45 ± 7 days of
treatment. Additional EB-focused endpoints include wound burden, patient-reported outcomes, and safety.
Results: Results of the primary endpoint are anticipated to be available by H2 2019.
Trial registration: ClinicalTrials.gov, NCT03068780. EudraCT, 2016–002066-32. Registered on 3 March 2017.
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Background
Epidermolysis bullosa (EB) is a rare group of autosomal,
dominant or recessive, genetic disorders characterized by
mechanical fragility of skin and mucosal surfaces. In EB,
the skin blisters in response to minor trauma or friction
[1]. There are > 30 genetically and phenotypically distinct
types and sub-types of EB caused by mutations in approxi-
mately 20 genes. Classification of EB is made according to
cleavage level within the skin ultrastructure, particular
morphological features, the causative gene, and the in-
heritance pattern [1].
Different sub-types of EB are characterized by differing
extents of extra-cutaneous involvement, including many
organs such as the gastro-intestinal and urinary tract,
larynx, eyes, bones, etc. These secondary complications
are mainly common in dystrophic (DEB) and junctional
EB (JEB) and less common in EB simplex (EBS) [1].
Most EB patients with the less severe forms of EB have a
normal life expectancy; however, severe forms, which
are generally evident in infancy, are life-limiting with
death resulting from infection, sepsis, failure to thrive,
or squamous cell carcinoma (SCC) [1].
There is currently no cure for any form of EB. Manage-
ment is centered on wound care and prevention, or on
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early treatment of complications as far as is possible. In
addition, patients with specific sub-types of EB also need
to be monitored for extra-cutaneous manifestations such
as corneal abrasions, dysphagia, osteoporosis, pseudosyn-
dactyly, and development of SCC [1]. The procedures for
wound care are meticulous, time-consuming, and often
very painful for patients. They also result in a great burden
for the patients and their families.
In common with other rare genetic diseases, robust
research activities are ongoing into the development of
recombinant genetic and stem cell therapies for EB.
However, these experimental approaches have not yet
resulted in viable routine therapeutic treatment options
[2]. By definition, gene therapy for EB is directed
towards repair of the erroneous DNA coding for the
non-functioning protein; therefore, each genotype
requires a separate gene- or protein-directed therapy.
Oleogel-S10 is an herbal preparation made from dry
birch bark extract (also referred to as triterpene extract
[TE]) combined with sunflower oil. Oleogel-S10 is
formulated as dry extract from birch bark: 10 mg dry
extract from birch bark and 90 mg refined sunflower oil
per 100mg of product. Betulin comprises 72 to 88% of
the birch bark extract. The other major marker sub-
stances include betulinic acid (0.5–6%), lupeol (2–8%),
oleanolic acid (0.1–2%), and erythrodiol (0.5–2%) [3]. TE
has activity on keratinocytes at various stages through-
out the wound-healing process, including modulation of
inflammatory mediators, and stimulation of keratinocyte
migration and differentiation [4, 5]. Other components
of birch bark extract besides betulin (e.g. oleanolic acid,
erythrodiol, betulinic acid, and lupeol) also have anti-in-
flammatory effects [6].
Oleogel-S10 was studied in a clinical trial program
including Phase 2 studies—one in split-thickness skin
grafts (STSG) and one in EB [7]—as well as Phase 3
studies in burns and STSG [8]. Studies in STSG and
burns support the development of Oleogel-S10 in EB
because EB wounds share morphological characteristics
of partial thickness wounds. Specifically, the level of skin
cleavage in the four major sub-types of EB primarily
extends, at a maximum, into the superficial dermis
[9]. In a small, Phase 2 proof-of-concept trial in
patients with EB (EudraCT 2010–019945-24), 12 wound
pairs in 10 patients with DEB were treated with Oleo-
gel-S10 in an open, blindly evaluated, controlled fashion.
Re-epithelialization was considered to be superior for
Oleogel-S10 compared with standard of care by both of
two blinded reviewers in five of the 12 cases. In three
cases, only one reviewer regarded Oleogel-S10-treated
wounds to have better re-epithelialization than standard
of care [7]. The relatively small size of this trial means that
firm conclusions on the efficacy of Oleogel-S10 in EB
cannot be made; however, the low incidence of adverse
events (AEs), and the possibility of improved efficacy over
standard of care, indicated that a Phase 3 trial was
warranted. Oleogel-S10 has been approved in Europe
for the treatment of partial thickness wounds in adults
[3] based on data from STSG and burns studies in
adults [8, 10].
EASE (Efficacy and safety of Oleogel-S10 in patients
with EB) is a randomized (1:1), double-blind, placebo-con-
trolled, superiority Phase 3 trial of Oleogel-S10 in patients
with EB ; therefore, it is the pivotal trial to support the de-
termination of the efficacy and safety of Oleogel-S10 in
EB. Due to the lack of other effective pharmacological in-
terventions in EB, EASE utilized standard-of-care wound
dressing with a placebo gel as a comparator. The primary
objective of the double-blind phase is to compare the effi-
cacy of Oleogel-S10 with placebo in the promotion of
healing of EB partial thickness wounds. This paper dis-
cusses the design and rationale of the EASE trial, the diffi-
culties of designing an appropriate study in the complex
setting of EB, as well as the general difficulties in designing
and conducting clinical trials in rare diseases. EASE is reg-
istered as NCT03068780, EudraCT 2016–002066-32; reg-
istered on 3 March 2017; https://clinicaltrials.gov/ct2/
show/NCT03068780.
Methods
Design
EASE is a two-phase study comprising a 90-day, double-
blind, randomized, placebo-controlled treatment phase,
followed by a 24-month, open-label, single-arm follow-up
phase (Fig. 1).
In the double-blind phase, patients are randomized 1:1
to either Oleogel-S10 plus standard-of-care wound
dressing or placebo, also with standard-of-care wound
dressing at least once every four days.
One EB target wound is assigned for each patient. The
target wound must involve loss of the epidermis, with
extension into the dermis allowable. The wound must be
10–50 cm2 in surface area and be > 21 days and < 9
months old according to the patient’s report. In the
Oleogel-S10 arm, Oleogel-S10 will be applied to the
target wound at the same time as the dressing changes.
Data from pre-clinical and clinical studies have shown
efficacy and safety within this range of dosing frequency.
Oleogel-S10 gel or corresponding placebo will be admi-
nistered topically to all wound areas on the body in a layer
of approximately 1-mm thickness and will be covered with
a non-adhesive wound dressing. This is the same thick-
ness that was applied in previous clinical studies of
Oleogel-S10 [7, 8, 11]. Standard-of-care dressing (patient
or physician choice) will be non-adhesive wound dressing
(e.g. soft silicone or foam) or equivalents as described in
the International Consensus Best Practice Guidelines for
Skin and Wound Care in Epidermolysis Bullosa [12]. In
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common with the Oleogel-S10 arm, wound dressings will
be applied at least once every four days according to
patient preference. Placebo will be applied in the same
manner as for Oleogel-S10. The placebo will be sunflower
oil formulated to have a consistency indistinguishable
from that of Oleogel-S10. In both arms, wounds will be
cleaned before application of dressings and Oleogel-S10.
The schedule of study visits is shown in Fig. 2.
Randomization will be stratified according to EB
sub-type. Within each sub-type, wounds will be stratified
by size (10–19 cm2, 20–29 cm2, and 30–50 cm2).
Randomization will be conducted according to blinded
Fig. 1 Trial design. *Children aged < 4 years may be included only after confirmation by the Independent Data Monitoring Committee (IDMC)
upon review of the safety and bioanalytical data available when at least six children aged 4–11 years, plus at least the same number of older
children and adults have completed days 45 and 90. †The unblinded interim analysis for sample size re-estimation will take place when
approximately 50% of patients have completed day 45 ± 7. Depending on the results of the sample size re-estimation, the IDMC will
recommend continuing with the initial sample size, increasing the sample size, or stopping the study for futility. DEB dystrophic epidermolysis bullosa,
JEB junctional epidermolysis bullosa, KS Kindler syndrome, SoC standard of care
Visit (V)
Day (D) D0 D60±7D30±7D14±5 D90±7 (EDBP)
‚Itch Man Scale‘/’
Leuven Itch Scale’
D7 +/-2
FLACC/Wong-Baker FACES®
Wound photography
Total body wound burden 
(EBDASI)
BSAP affected by EB partial 
thickness wounds
Impact of wounds on sleep
(W-QoL)
Days missed from school/work
Response to treatment (TSQM)
V2 CCCV1 V6V4V3 V7a
Flexible visit up to 1 week + 2 
days after first complete 
closure
Safety laboratory tests
Voluntary capillary blood for
betulin analysis
Assessment by investigator
Documentation by study team member
D45±7
V5
First complete target 
wound closure
Fig. 2 Study visit schedule. BSAP body surface area percentage, CCC confirmation of complete closure of the EB target wound, D day, EBDASI
Epidermolysis Bullosa Disease Activity and Scarring Index, EDBP end of double-blind phase, FLACC Face, Legs, Activity, Cry, Consolability scale,
TSQM Treatment Satisfaction Questionnaire for Medication; V visit, W-QoL Wound-Quality of Life Questionnaire
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patient number and the randomization key will be held
solely by an independent statistician. Patients are
randomized by accessing the patient in the electronic
trial database (RAVE) and randomizing him/her in the
section ‘Randomisation’ in the electronic clinical report
form (eCRF). Here, randomization date, time, number,
kit number, and date of allocation are automatically
populated once it is confirmed that the patient is ready
for randomization and entered how many kits need to
be allocated. In the event of an emergency, unblinding is
conducted electronically with full documentation of the
unblinding request and sample size re-estimation.
An unblinded, interim efficacy analysis and sample size
re-estimation will be conducted when 50% of patients
have reached day 45 ± 7. Depending on the results of the
sample size re-estimation, the Independent Data Moni-
toring Committee (IDMC) will recommend continuing
with the initial sample size, increasing the sample size,
or stopping the study for futility. The IDMC will review
blinded safety data when at least six children aged 4–11
years, plus at least the same number of older children
and adults, have completed days 45 and 90.
During the open-label phase, Oleogel-S10 will con-
tinue to be applied in conjunction with standard-of-care
wound dressings. Once the last visit for the randomized
phase has been completed and the return of the corre-
sponding unused study medication has occurred, the
patient may enter the single-arm, open-label, 24-month
follow-up period. The last visit on day 90 of the rando-
mized phase corresponds to the first visit of the
follow-up phase, whereby photographic data from the
former will become the baseline for the latter. All
patients will receive Oleogel-S10 in accordance with
the method and timings used in the randomized
phase. Compliance will be assessed via records of gel
tube dispensing, weighing, and return of spent and
unused containers.
After the end of follow-up, it is intended that patients
will receive Oleogel-S10 on a named-patient basis, where
feasible as per local regulation, until approval of the
investigational product.
Endpoints
The primary objective of the EASE trial is to compare
the efficacy of Oleogel-S10 with placebo. The primary
endpoint used to determine efficacy is the proportion of
patients with first complete closure of the target EB
wound within 45 ± 7 days of treatment (Table 1). The
assessment for the primary endpoint follows the U.S. Food
and Drug Administration (FDA) Guidance for Industry
‘Chronic Cutaneous Ulcer and Burn Wounds – Developing
Products for Treatment’ [13]. There is no guidance on the
specified time of an acute EB wound becoming chronic,
although the consensus meetings on the development of
the Instrument for Scoring Clinical Outcome of Research
for Epidermolysis Bullosa (iscorEB) [14] have defined
wounds in EB to be chronic if they are present for > 6
weeks [14]. Therefore, the closure time target of 45 days,
plus the 21-day baseline wound age is in line with this
chronicity (i.e. > 42 days).
The definition of wound closure for the EASE study is
first appearance of complete re-epithelialization without
drainage. Once the target wound is deemed closed based
on clinical assessment by the Investigator, a Confirmation
of Wound Closure visit will occur within 7 + 2 days.
Study sites will educate patients and parents verbally
and through the use of photographs as to what
re-epithelization means and how to recognize this for
their wounds. Patients and parents will be instructed
to contact the site as soon as they believe that re-e-
pithelization without drainage has occurred – the site will
schedule the next planned study visit as soon as possible
or arrange for the patient to attend an unscheduled visit
for the purpose of wound assessment.
Table 1 Primary and secondary outcome measures
Primary endpoint • Proportion of patients with complete closure of the target wound within 45 ± 7 days of treatment
Secondary endpoints • Time to wound closure up to 90 ± 7 days of treatment
(key secondary endpoint)
• Incidence of first complete wound closure of EB target wound at different time points (see Fig. 2)
• Change from baseline in EB target wound size
• Change in total body wound burden over time
• Change in percentages of TBSA affected by EB partial thickness wounds
Patient-reported outcomes • Change from baseline in background and procedural pain after wound dressing change
• Change from baseline in itching before wound dressing change
• Response to treatment
• Change from baseline in sleep quality
• Number of days missed from school or work
Safety endpoints • Incidence, severity, and relatedness of AEs
• Local tolerability
• Laboratory findings
• Incidence and severity of wound infections
AE adverse event, EB epidermolysis bullosa, TBSA total body surface area
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The key secondary efficacy endpoint of the double-
blind phase will be the comparison in efficacy of Oleo-
gel-S10 versus placebo according to the time to first
complete closure of the EB target wound until day 90 ± 7.
The time taken to achieve complete wound healing is a
clinically important endpoint for the assessment of the
potential benefit of a wound-healing treatment in EB.
Faster wound healing results in fewer symptoms related to
open wounds (e.g. pain and itching) and would be
expected to decrease the likelihood of wound infection.
Additional secondary endpoints are shown in Table 2, and
include patient-reported outcomes (PROs) and reduction
of total body surface area wound burden.
The primary rationale of the open-label follow-up is
to obtain long-term safety data, but efficacy data will
continue to be collected according to the methods of
the double-blind phase.
For the assessment of wound closure and re-epithelialization,
the investigator will photograph the EB target wound
and all other wounds that match target wound criteria
with the ARANZ Silhouette® system. This system measures
accurately, precisely, and reliably, provides high quality
imaging, and a standardized documentation. The system
consists of the SilhouetteStar™ point of care imaging device
that captures the wound image using three-dimensional
(3D) laser technology and SilhouetteConnect™ software
that creates a 3D model of the wound based on photo-
graphic data, derives measurements of the model, and
records standardized notes. Automatic flash ensures
consistent lighting across images.
During screening, the investigator will select the EB
target wound and two appropriate anatomical landmarks
on either side of it. The baseline reference image will be
taken with these landmarks. Future visits will refer to
the baseline reference image to ensure that the correct
wound is assessed. All other wounds that match target
wound criteria will be photo-documented similarly.
Post-treatment assessments will be made within one
week of wound closure to determine durability of healing.
This one-week window was selected as an adaptation of
an FDA requirement for confirmatory assessment of
wound closure two weeks after first determination, as used
for wounds such as diabetic ulcers. For the EASE trial, the
two-week confirmatory assessment was reduced to one
week because of the tendency of EB wounds to re-open
per the normal course of the disease state. This FDA re-
quirement poses a major challenge for reaching meaning-
ful results in the context of EB, where re-wounding is a
common occurrence [15]. Data collection forms for
wound assessment are provided in the protocol. These
forms are part of an overall eCRF that documents all
patient data from screening, through baseline, treatment,
and follow-up. The eCRF is completed by the investigator
and is subject to a data management procedure (docu-
mented separately from the protocol) that included review
and query of errant data. A contract coder will code any
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Male and female patients with JEB, DEB, or Kindler syndrome aged≥ 4
years (children aged < 4 years may be included only after confirmation
by the Independent Data Monitoring Committee upon review of the
safety and bioanalytical data at the interim safety review stage)
Patients with an EB target wound (i.e. EB partial thickness wound of
10–50 cm2 in size aged ≥ 21 days and < 9 months) with no signs of
local infection
Patient and/or his/her legal representative has/have been informed,
has/have read and understood the patient information/informed
consent form, and has/have given written informed consent
Patient and/or his/her legal representative must be able and willing to
follow study procedures and instructions
Patients with EBS
EB target wound with clinical signs of local infection
Use of systemic antibiotics for wound-related infections within 7 days before
enrollment
Administration of systemic or topical steroids (except for inhaled,
ophthalmic, or topical applications, such as budesonide suspension for
esophageal strictures [e.g. Pulmicort Respules® 0.25 mg/2mL
or 0.5 mg/2mL]) within 30 days before enrollment
Immunosuppressive therapy or cytotoxic chemotherapy within 60 days
before enrollment
Patient has undergone stem cell transplant or gene therapy for the
treatment of inherited EB
Current and/or former malignancy including basal cell carcinomas and
squamous cell carcinomas
Enrollment in any interventional study or treated with any investigational
drug for any disease within 4 weeks before study entry
Factors present in the patient and/or his/her legal representative that could
interfere with study compliance such as inability to attend scheduled study
visits or compliance with home dressing changes
Pregnant or nursing women
Women of childbearing potential including post-menarchal female
adolescents and men who are not willing to use an effective form of birth
control with failure rates < 1% per year (e.g. implant, injectable, combined
oral contraceptive, intrauterine contraceptive device, sexual abstinence,
vasectomy, or vasectomized partner) during participation in the study
(and at least 3 months thereafter)
Patient is a member of the investigational team or his/her immediate family
Patient lives in the same household as a study participant
EB epidermolysis bullosa, DEB dystrophic EB, EBS EB simplex, JEB junctional EB
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AEs according to MedDRA and any concomitant medi-
cations according to the World Health Organization
Drug Dictionary.
Safety will be assessed by the overall incidence, sever-
ity, and relatedness of AEs. These will be captured via
the eCRF and subject to the same data management and
query procedure as the other endpoints.
PROs will be assessed according to the Itch Man Scale
[16], the Leuven Itch Scale [17], the Face, Legs, Activity,
Cry, Consolability Pain Rating Scale [18], the Wong-Baker
FACES® Pain Rating Scale [19], the impact of wounds on
sleep quality [20], Treatment Satisfaction Questionnaire
for Medication [21], and number of days missed from
school or work. These endpoints will be applied according
to age category. Data collection forms for PROs are
provided in the protocol.
For the open-label, follow-up phase, key endpoints are
incidence and severity of AEs, local tolerability, and
laboratory-related safety data. Efficacy endpoints from
the randomized trial will also be evaluated.
Appropriately trained monitors will periodically contact
the site and perform site visits in accordance with appli-
cable regulations, Good Clinical Practice, and sponsor-ap-
proved procedures.
Patients
EASE will enroll male and female patients aged ≥ 4 years
with JEB, DEB, or Kindler syndrome. EASE will not
enroll patients with EBS because this sub-type of EB
often only has a mild phenotype with minor blisters [12,
22] and hence would be the least likely sub-type of EB
to derive a treatment benefit; therefore, inclusion of EBS
patients would be likely to dilute the overall treatment
effect. Exclusion of EBS patients will help to ensure that
healing rates in the control arm of the study will not be
too high and thereby avoid reduction in statistical power
while increasing the likelihood of demonstrating a statis-
tically significant treatment effect in other treatment
groups. Detailed inclusion and exclusion criteria are given
in Table 2. Children aged < 4 years may be included only
after confirmation by the IDMC upon review of the safety
and bioanalytical data at the interim safety review stage.
The IDMC will evaluate safety parameters, including any
off-target, systemic effects of Oleogel-S10. Additional
patients aged < 4 years will need to be ≥ 21 days old
because of the need for EB wounds to be ≥ 21 days
in evidence.
Recruitment and retainment are aided by patient bro-
chures, an informed consent flipchart, a study flowchart,
a dosing guide, a booklet for children, an emergency
information card, and cards that cover inclusion and
exclusion criteria.
EASE is conducted in multiple countries (Fig. 3) in an
outpatient, home-care setting in accordance with the
principles of the Declaration of Helsinki. The trial has
received institutional review board approval at all
participating sites. All patients/guardians provide written
informed consent before enrollment.
Patients will be expected to complete the randomized
phase before enrollment in the open-label phase. How-
ever, if a patient discontinues the randomized phase pre-
maturely due to worsening of the EB target wound status
or due to EB target wound infection, the investigator may
decide to allow the patient to enter the follow-up phase
prematurely or else discontinue the study.
Until complete closure and confirmed epithelialization
during both the double-blind phase and follow-up phase
of the study, patients will not be permitted to use
sulfadiazine silver, silver dressing, topical antibiotics, or
topical steroids for the treatment of study target wound
areas and other wounds matching target wound criteria,
as these products have the potential to either impact
wound healing or introduce assessment bias in photo-
graphic wound area measurement/assessment. These
treatments will be allowed on single, non-target EB
wounds. Application of creams and ointments on
areas on the patient’s body that are affected by EB
wounds will not be permitted during the double-blind
phase of the study. Until M3 ± 14 days of the
open-label follow-up, systemic steroids - except for
inhaled, ophthalmic, or topical applications, such as
budesonide suspension for esophageal strictures (e.g.
Pulmicort Respules® 0.25 mg/2 mL or 0.5 mg/2 mL) -
and immunosuppressives are not permitted, nor is it
allowed to use systemic antibiotics with the expressed
purpose of reducing EB target wound area.
Statistical considerations
The sample size estimation assumed a true control rate
for the primary endpoint of 27% based on estimation of
the expected wound-healing rate in the control arm of
EASE, which in turn was calculated using wound-heal-
ing rates from the ESSENCE trial of allantoin cream in
EB. Based on a two-sided two-sample comparison of
proportions at the alpha = 0.05 level of significance, a
sample size of 91 patients in each group (total 182) will
provide 80% power to detect an improvement of 20 per-
centage points (i.e. a rate of 47% in the Oleogel-S10
arm). To account for an estimated drop-out rate of 5%,
192 patients are planned to be enrolled (96 patients
per arm).
For the primary endpoint, the proportion of patients
with first complete closure of the EB target wound within
45 ± 7 days based on clinical assessment by the investi-
gator in the Oleogel-S10 and placebo treatment groups
will be compared using the Cochran-Mantel-Haenszel
(CMH) test, stratified by EB sub-type and target wound
size class. Due to the interim analysis, the final statistical
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analyses of the primary endpoint will be performed
based on the Cui, Hung, Wang approach using a
weighted statistic [23].
If the primary efficacy endpoint demonstrates super-
iority of Oleogel-S10 at the two-sided 5% significance
level then the key secondary endpoint, time to first
wound closure, will be tested at the two-sided 5% signi-
ficance level using the non-stratified log-rank test. This
hierarchical testing strategy ensures that the overall
significance level remains at 5% without the need for
adjustment due to multiple comparisons. Additionally,
the stratified log-rank test, with consideration of EB
sub-types as strata, will be conducted on the full analysis
set. Further potential risk factors will be investigated by
a Cox regression model on full analysis set with adjust-
ment for EB sub-types, target wound size class, and
additional baseline factors.
The secondary endpoint of the proportion of patients
with first complete closure of the EB target wound will be
analyzed in the same manner as the primary endpoint.
The percentage change from baseline in EB target wound
size will be analyzed at each visit using an analysis of
covariance (ANCOVA) model including treatment group
and EB sub-type as fixed effects and size of target wound
at baseline as a covariate. The 95% confidence intervals
for the difference in least squares means between treat-
ment groups will be calculated. Additionally, treatments
will be compared using a two-sided Wilcoxon Rank Sum
test stratified by EB sub-type (van Elteren test). A sensiti-
vity analysis will be performed using the assessment of all
photographs of EB partial thickness wounds. The changes
from baseline in total body wound burden, in body surface
area percentage (BSAP) of total body surface area (TBSA)
affected by EB partial thickness wounds, in the impact of
wounds on sleep, and the treatment response will be
analyzed correspondingly. The incidence rates of wound
infection between treatments will be compared using a
CMH test considering the strata of EB sub-type and target
wound size class. Maximum severity will be compared
between treatments using a two-sided Wilcoxon Rank
Sum test stratified by EB sub-type and target wound
size class (van Elteren test). The change from baseline
in “background pain,” “procedural pain,” and itching
will also be compared using a two-sided Wilcoxon
Rank Sum test stratified by EB sub-type and target
wound size class (van Elteren test).
Fig. 3 Study locations. Data correct July 2018
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For the primary endpoint, an individual with missing
data will be defined as not having achieved complete
closure. For the key secondary endpoint, participants
will be censored at the date last known to have not
achieved complete closure. Missing data for all other
endpoints will be imputed according to last observation
carried forward.
Termination criteria
Patients will be withdrawn from the study if they meet
any of the following criteria: worsening of the EB target
wound status or EB target wound infection as assessed by
the investigator (optional, as per decision of the investiga-
tor); withdrawal of patient’s and/or his/her legal represen-
tatives consent; patient is non-compliant with the study
procedures or medications in the opinion of the investiga-
tor; progression of a medical condition, which, in the
opinion of the investigator, should preclude further par-
ticipation of the patient in the study; administration of
non-permitted concomitant medication(s); investigator’s
decision that a change of therapy is in the patient’s best
interest; pregnancy as evidenced by a positive pregnancy
test; or occurrence of an AE, which makes discontinuation
desirable or necessary in the investigator’s and/or the pa-
tient’s opinion.
Study locations
EASE is an international study conducted in 22 countries,
with a further four countries in a possible expansion
(Fig. 3). Sites in the United States will join the trial
following approval of the protocol by the FDA.
Results
The first patient was enrolled in EASE in the first quarter
of 2017. The interim analysis conducted by the IDMC
recommended that the trial should continue with an in-
crease of 48 patients in the study to a total of 230 evalu-
able patients in order to achieve 80% statistical power.
The analysis was conducted using unblinded efficacy data
received by the IDMC for the primary endpoint from the
first half of the study. A safety analysis conducted by the
IDMC of data of all visits performed up to 31 December
2018 recommended to expand the inclusion of children
with EB to all ages, i.e. ≥ 21 days and < 4 years per proto-
col. The study is predicted to complete enrollment in
Quarter 3 of 2019. The last patient is expected to reach
day 90 in Quarter 4 of 2019. EASE is expected to provide
results from its complete dataset Quarter 4 of 2019. Re-
sults from EASE will be published and summary data
will be made available on EudraCT and ClinicalTrials.-
gov. Publications will be prepared in accordance with
Good Publication Practice and the principles set out by
the International Committee of Medical Journal Edi-
tors. Editorial support may be sought.
Discussion
The EASE trial is designed as the pivotal study forming
the basis of regulatory submissions for approval of the
use of Oleogel-S10 in combination with standard of care
to accelerate wound healing in patients with EB. The
trial has an inclusive design that includes all types of
inherited EB except EBS and includes all patients aged
≥ 4 years, with expansion into younger ages based on
protocol amendment 5 reflecting the IDMC decision after
the unblinded interim safety analysis.
Oleogel-S10, a formulation of dry extract from birch
that modulates inflammatory mediators and stimulates
keratinocyte migration and differentiation [4, 5], is
expected to show efficacy in EB due to its demonstrated
efficacy on morphologically similar STSG and burn
wounds. The drug has also shown wound-healing
activity in a Phase 2 trial in EB where it has also
been associated with good levels of safety and tolerability.
The EASE trial is faced with a range of issues that are
common to the design of other trials for wound-healing
interventions and that challenge the convention on how
clinical trials ought to be designed. In general, evidence-
based medicine demands the highest quality data from
randomized, controlled trials. The use of standard-of-care
dressings means that local study site practices can be
used, which enables the trial to accurately reflect real
clinical settings [24].
Primary endpoint
The selection of the primary endpoint is an important
consideration of the EASE trial. Difficulties in selecting
endpoints in wound-healing trials have been encountered
in the past. The recent ESSENCE trial (NCT02384460),
which evaluated the efficacy of SD-101 6% allantoin
cream, utilized two primary endpoints of time to complete
target wound closure (within three months) and the
proportion of patients experiencing complete closure of
their target wound (also within three months). In that
study, 49% of patients on SD-101 experienced wound
closure within the three-month treatment period com-
pared to 54% of the placebo patients (data in press reports
only [25]). Thus, the data did not demonstrate evi-
dence of a treatment effect and development of SD-101
was cancelled.
For the EASE trial, the sponsor is obliged to select a
primary endpoint derived from historical trials of wound-
healing therapies. In these trials, the endpoints are based
on complete healing of the selected target wound and
a comparison of how many closures occur in a given
timeframe. These stipulations are governed by health
authorities [13]. In its guidance, the FDA has listed
four different kinds of endpoints that are acceptable
for deriving clinical benefit in wound healing. These
include: incidence of complete wound closure; speed
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of wound closure; facilitation of surgical wound closure;
and “quality of healing,” which encompasses cosmesis and
skin function [13]. However, in EB, these endpoints ge-
nerate a number of problems. For incidence and speed of
complete wound closure, the relapsing, remitting course
of EB means that some wounds never fully close. Facili-
tation of surgical closure is not relevant to EB because of
the wide area of involvement whereby wounds resemble
partial thickness wounds rather than incisions. In a recent
study of patients with recessive DEB (RDEB), Solis et al.
examined the size and chronicity of wounds in RDEB.
Their cross-sectional survey found that patients with
the condition have chronic wounds that can persist for
years and that scars form with frequent healing and
reblistering within weeks [26]. Two types of wounds
were identified—recurrent and chronic open [26]—and,
by nature, neither of these are suited to assessment by
the four criteria set out by the FDA. Delegates from the
Dystrophic Epidermolysis Bullosa Research Association
(DEBRA) USA met with the FDA in April 2018 to discuss
pathways to drug approval; a report from that meeting
is pending.
Many of the themes that were discussed at the DEBRA
meeting were addressed in the new FDA guidance [27].
This guidance has indicated that clinical trials in EB are re-
ceiving special attention that differentiates them from cli-
nical trials in burns and other wound types [27]. Notably,
the draft guidance suggests that clinically meaningful
improvements may involve the improvement of only
one symptom or sign of EB and may require only one
well-controlled trial to demonstrate efficacy depending on
the persuasiveness of the data. Among the symptoms con-
sidered by the FDA are significant relief from itching, pain,
blister prevention, and wound healing. The FDA suggests
that PROs ought to be included in clinical trials in
EB, but that findings of that nature would not be
definitive for determining efficacy.
Other drug manufacturers have looked at different end-
points in EB. In a recent Phase 2/3, randomized, crossover,
placebo-controlled trial of diacerein cream in EBS (Castle
Creek), the primary endpoint was the proportion of
patients with a reduction of > 40% from baseline in num-
ber of blisters within the treated areas through the end of
each four-week treatment episode [28]. Among the
secondary endpoints was the proportion of patients with
recurrence of initial blister numbers plus or minus 10% at
the end of both treatment periods. The study met its
primary endpoint for 85% of patients in the first treatment
period [28]. However, it is important to bear in mind that
EBS wounds do not open in the same way that wounds
open in DEB, JEB, and Kindler syndrome [22]. A further
trial of diacerein (NCT03154333) used the primary end-
point as the proportion of participants who achieve ≥ 40%
reduction in total area affected by EBS lesions. This is in
line with the idea of measuring wound burden in EB ra-
ther than wound closure.
Secondary endpoints: patient-reported outcomes
The current battery of assessments for wound healing
may ignore the types of improvement that are most val-
ued by patients and physicians. Frew et al. have devel-
oped a quality-of-life questionnaire specific to EB. As
part of the generation of the instrument, researchers
conducted interviews with 26 EB patients, 33 family
members, and 11 healthcare professionals concerned
with EB care [29]. In developing their instrument, Frew
et al. found that pain, general movement, getting out,
meeting friends, and financial considerations were
important to patients with EB [29]. These factors are
particularly important in EB where patients and carers
enduring painful chronic disease with elaborate dressing
changes have an important contribution to offer in terms
of what is of benefit to them.
Several secondary endpoints of the EASE trial validate
optional further treatment benefits. Five secondary end-
points are based on PROs, namely the change from base-
line in “background pain” and “procedural pain,” in “itch,”
in the impact of wounds on sleep, the evaluation of the
patient’s satisfaction with treatment, and the days missed
from school or work due to EB. The 2009 FDA guidance
for industry “Patient-reported Outcome Measures:
Use in Medical Product Development to Support
Labeling Claims” [30] recommends to evaluate a PRO in-
strument, among others, based on the target patient popu-
lation and the PRO instrument’s conceptual framework.
Mordin et al. conducted a review to evaluate health-
related quality-of-life (HRQoL) measures for use in a
pediatric patient population (aged 3 to < 18 years) with
EB [31]. They identified 40 eligible publications and
assessed them according to the 2009 FDA guidance on
PRO measures and the 2005 European Medicines
Agency (EMA) reflection paper on the use of HRQoL
measures. In particular, they investigated the practicality
of the instruments including the availability of age-ap-
propriate version(s), the number of items (i.e. the
respondent burden), and the recall period. In addition,
content validity in terms of relevant content for patients
with EB as well as the age relevance of concepts
addressed has been assessed. Psychometric properties
such as validity and reliability (test–retest, internal
consistency) have been evaluated. Finally, they have
checked whether the HRQoL instruments have been
used in previous EB studies and whether any respon-
siveness to change has been observed. Mordin et al.
concluded that a HRQoL instrument evaluating age-
appropriate concepts for EB was not available and
that content validity was lacking in the majority of
measures evaluated [31].
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In addition, most items of disease-specific HRQoL
scores would not be changed by the treatment with an
investigational medicinal product such as Oleogel-S10,
as demonstrated by the studies of Lara-Corrales et al.
and Venugopal et al. [22, 32]. Although wound size
reductions of > 50% have been observed in both studies,
neither the Dermatology Life Quality Index (DLQI)/
Children’s Dermatology Life Quality Index (CDLQI) nor
the Quality of Life in Epidermolysis Bullosa (QOLEB)
were able to detect significant changes [22, 32]. Similarly,
treatment with Oleogel-S10 is expected to reduce the total
body wound burden of EB wounds. However, this fact
would not be reflected in any of the 17 items of the
QOLEB, as most items rather measure disease damages
and their consequences than disease activity and its
impact. Hence, the concepts “pain,” “itch,” “impact of
wounds on sleep,” and the patient’s satisfaction with treat-
ment are assessed with concept-specific instruments.
Concepts measured: pain, itch, impact of wounds on
sleep, patient’s satisfaction with treatment, and days
missed from school or work
For the development of the iscorEB [14], patients with
EB were asked for their perception of disease severity.
“Pain” and the “extent and healing of wounds” were the
most common items listed by patients. Fine et al.
assessed pain in children with EB and reported that only
12–14% of children with EBS, JEB, and dominant DEB
and 5% of children with RDEB were pain-free [33].
Oleogel-S10 is suggested to reduce both “background”
pain due to the decrease of total body wound burden
and “procedural” pain because of less adherence to
wound dressings. The 2009 FDA guidance states that
patients from the target population might be queried
about pain severity using a single-item PRO instrument
to assess the efficacy of treatment on pain. Therefore, an
existing single-item instrument was chosen that reliably
measures “pain severity” in children enrolled in the
clinical trial. In patients aged ≥ 4 years, the Wong-Baker
FACES® Pain Rating Scale is used for assessing “back-
ground” pain before wound dressing change and “pro-
cedural” pain after wound dressing change. As the
2009 FDA guidance discourages proxy-reported out-
come measures and recommends reports that include
only those events or behaviors that can be observed
instead [30], the Face, Legs, Activity, Cry, Consolability
scale is used for assessing “background” pain before
wound dressing change and “procedural” pain after wound
dressing change in patients aged < 4 years.
Patients with EB rate itch as the most bothersome com-
plication; 87% of patients report itch to be present at rest.
Itching correlates positively with self-reported EB severity
and with total body wound burden. It is strongest in healing
wounds (p < 0.001), skin around wounds (p < 0.001), dry
skin (p = 0.001), and infected wounds (p = 0.002) [34].
Oleogel-S10 is supposed to decrease itch by reducing
the total body wound burden. Similar to the evaluation
of pain severity, a single-item PRO instrument is used
to assess the efficacy of treatment on itch. Patients aged
≥ 4 years and up to 13 years are asked to assess itching
using the Itch Man Scale. In patients aged ≥ 14 years,
itch is evaluated using the Leuven Itch Scale.
When patients with EB were asked for their perception of
disease severity as basis for the development of the iscorEB,
“sleep” was one of the items chosen for inclusion in the score
[14]. The sleeping domain asks the patient how much sleep
disturbance he/she typically experienced in the last four
weeks [14]. Although this patient-derived item is part of the
iscorEB, it rates sleep disturbance per se without relating it
to, for example, the total body wound burden and its impact
on sleep. The only disease-specific instrument that deliber-
ately asks for the impact of wounds on sleep is the Wound
Quality of Life Questionnaire (W-QoL) developed by Blome
et al. in 2014 and based on the Freiburg Quality of Life As-
sessment for Wounds, the Cardiff Wound Impact Schedule,
and the Würzburg Wound Score [20]. Since most of
the 17 items of the W-QoL questionnaire relate to
(chronic) wounds, but not to EB, the single-item PRO
regarding the impact of wounds on sleep is the only
W-QoL measure used in EASE.
The patient’s satisfaction with treatment is assessed with
an existing PRO instrument [35]. The PRO on days
missed from school or work is based on the Work Prod-
uctivity and Activity Impairment Questionnaire Psor-
iasis, Version 2 [36].
Patient population
The underlying genetic nature of EB is a further factor
that affects clinical outcome versus established end-
points for wound-healing trials. In burns, for example,
once the injuring stimulus is removed, the wound is free
to heal without risk of re-injury from the original stimu-
lus. In diabetic skin lesions, level of wounding is asso-
ciated with the degree of glycemic control [37]. In EB,
there are specific gene mutations that result in skin
cleavage [1]; these cannot be corrected by application of
a non-causal therapeutic (gene, cell, or protein therapy).
Therefore, in EB, there is a constant molecular drive to
re-injure, regardless of treatment, which results in a
highly dynamic situation possibly unsuited to assessment
of wound closure.
While the inclusivity of EASE in accepting patients with
multiple types of EB (except EBS) is a strength in terms of
understanding drug efficacy across EB sub-types, this also
introduces significant variation in patient baseline charac-
teristics that could have a bearing on the statistical ana-
lysis of the primary endpoint. The study also deviates
from the Phase 2 design of intra-patient controls, thereby
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introducing more variability into the statistical outcome.
Additionally, while genetic testing for accurate diagnosis
of patients would be desirable, in order to enroll the
required sample size, the EASE trial includes some centers
where genetic testing is not standard practice. Therefore,
some potential uncertainty about accuracy of clinically
diagnosed sub-types remains. This has implications for
any potential future trials in EB.
Sample size is a problem in rare diseases in general.
The rarity of the diseases under study means that there
is an ongoing problem with patient availability that
can ultimately affect statistical power. This issue is
frequently confounded by competition between trial
recruitment programs when more than one drug de-
veloper is investigating therapeutics in the same indi-
cation. Additionally, EB families get into a routine
with dressing changes [12] and can be reticent to do
anything that might disrupt that. This factor can further
influence the availability of patients willing to consent to
non-standard-of-care therapy.
Study design
EASE was originally conceived as an unblinded trial because
of difficulties associated with formulating a suitable placebo
control. In order to offset the problems associated with run-
ning an unblinded trial, an intra-patient crossover design
was considered. A crossover design for this trial would
also have been beneficial in terms of observing study
drug activity across a greater range of wound types.
However, the treatment period for each intervention
(Oleogel-S10 and control) may not be long enough to
enable wounds to return to baseline, as required for a
design of this type. Therefore, EASE was designed
with a single randomized treatment period. In the
event, a placebo control was formulated and the trial
was designed with standard study drug versus placebo
treatment arms, thereby introducing a placebo arm
that is technically not necessarily representative of
standard of care. In fact, the standard of care differs
so greatly from patient to patient in EB [12], that it
is essentially impossible to define a homogenous
standard of care arm in EASE. These issues inherent
in crossover designs would apply to many wound-
healing trials in lesions typical of EB.
At the time of publication, the EASE trial was recruiting
participants (Additional file 1).
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 117 kb)
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